<DOC>
	<DOCNO>NCT00330616</DOCNO>
	<brief_summary>This study obtain clinical experience 323U66 SR elderly patient depression repeat-dose 323U66 SR 300mg/day , conduct exploratory investigation safety , efficacy pharmacokinetics profile elderly patient depression .</brief_summary>
	<brief_title>Study Of Bupropion SR ( 323U66 ) In Patients With Major Depressive Disorder In Japan</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Inclusion criterion : Target disease : Patients diagnose follow primary disease current major depressive episode least 8 week basis DSMIVTR criterion . Major Depressive Disorder , Single Episode ( 296.2x ) ( exclude psychotic feature ) Major Depressive Disorder , Recurrent ( 296.3x ) . ( exclude psychotic feature ) HAMD ( 17 item ) total score &gt; /=18 . Age : &gt; /=65 year old ( time inform consent ) Gender : Male female . Inpatient outpatient status : Either Informed consent : The subject himself/herself must give write informed consent . Exclusion criterion : Patients predisposition seizure ( currently past history seizure , febrile convulsive seizure infancy , cerebral tumour , cerebrovascular disorder head injury , family history idiopathic seizure , patient diabetes treat oral hypoglycaemics insulin , use drug lower threshold seizure ) Patients currently past history follow disorder : Anorexia nervosa ( DSMIVTR 307.1 ) Bulimia nervosa ( DSMIVTR 307.51 ) Patients history manic episode Patients past current DSM IVTR diagnosis schizophrenia psychotic disorder Patients current DSMIVTR Axis II diagnosis ( e.g. , antisocial borderline personality disorder ) Patients start psychotherapy ( except supportive psychotherapy aim therapeutic efficacy unlikely affect efficacy evaluation ) standardize cognitive behaviour therapy within 12 week prior start treatment phase Patients diagnosis substance abuse ( alcohol drug ) DSMIVTR criterion diagnosis substance dependence within 1 year prior start treatment phase Patients receive electroconvulsive therapy within 24 week prior start treatment phase Patients take MAO inhibitor ( selegiline hydrochloride ) within 2 week prior start treatment phase Patients take another investigational drug within 12 week prior start pretreatment phase Patients attempt suicide within 24 week prior start treatment phase , patient score suiciderelated item HAMD &gt; /=3 , patient risk suicide judge high investigator ( subinvestigator ) . Patients risk homicide judge high investigator ( subinvestigator ) . Patients history hypersensitivity 323U66 Patients serious cerebral disease Patients ECG clinical evidence cardiac condition investigator ( subinvestigator ) assess subject predispose ischemia arrhythmia Patients serious physical symptom ( i.e . cardiac/hepatic/renal disorder , hematopoietic disorder ) . The index seriousness Grade 3 `` Criteria classification seriousness adverse drug reaction pharmaceutical product , etc . '' ( PAB/PSD No.80 1992 ) . Patients history complicate carcinoma malignant tumour . Patients whose major depressive disorder due direct physiological effect general medical condition ( example , hypothyroidism , Parkinson 's disease , chronic pain ) Patients systolic blood pressure &gt; /=160 mmHg diastolic blood pressure &gt; /=100 mmHg start Treatment Period Patients diagnose dementia Patients inappropriate participate study judgement investigator ( subinvestigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>WELLBUTRIN</keyword>
	<keyword>elderly</keyword>
	<keyword>depression</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>